Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BHC NASDAQ:DYN NASDAQ:MLTX NASDAQ:SRPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.19-3.1%$6.88$4.25▼$9.85$2.29B0.432.50 million shs3.48 million shsDYNDyne Therapeutics$17.12+3.8%$13.70$6.36▼$35.68$2.44B1.092.58 million shs1.78 million shsMLTXMoonLake Immunotherapeutics$9.52+0.6%$37.75$5.95▼$62.75$611.48M1.11.67 million shs1.65 million shsSRPTSarepta Therapeutics$22.80+4.2%$19.88$10.41▼$138.81$2.23B0.516.26 million shs3.71 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+2.16%+5.90%-5.20%-5.76%-21.00%DYNDyne Therapeutics+0.86%+0.43%+25.02%+65.73%-49.04%MLTXMoonLake Immunotherapeutics-1.46%+0.85%-81.99%-82.82%-79.70%SRPTSarepta Therapeutics-2.58%-6.21%+22.09%+83.49%-83.15%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBHCBausch Health Cos$6.19-3.1%$6.88$4.25▼$9.85$2.29B0.432.50 million shs3.48 million shsDYNDyne Therapeutics$17.12+3.8%$13.70$6.36▼$35.68$2.44B1.092.58 million shs1.78 million shsMLTXMoonLake Immunotherapeutics$9.52+0.6%$37.75$5.95▼$62.75$611.48M1.11.67 million shs1.65 million shsSRPTSarepta Therapeutics$22.80+4.2%$19.88$10.41▼$138.81$2.23B0.516.26 million shs3.71 million shsThe 10 Best AI Stocks to Own in 2025Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBHCBausch Health Cos+2.16%+5.90%-5.20%-5.76%-21.00%DYNDyne Therapeutics+0.86%+0.43%+25.02%+65.73%-49.04%MLTXMoonLake Immunotherapeutics-1.46%+0.85%-81.99%-82.82%-79.70%SRPTSarepta Therapeutics-2.58%-6.21%+22.09%+83.49%-83.15%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBHCBausch Health Cos 2.00Hold$9.0045.28% UpsideDYNDyne Therapeutics 2.94Moderate Buy$34.0798.99% UpsideMLTXMoonLake Immunotherapeutics 2.07Hold$36.00277.52% UpsideSRPTSarepta Therapeutics 2.03Hold$34.4653.05% UpsideCurrent Analyst Ratings BreakdownLatest MLTX, DYN, BHC, and SRPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/24/2025BHCBausch Health CosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/24/2025DYNDyne TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/22/2025SRPTSarepta TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetUnderperform$16.00 ➝ $18.0010/14/2025DYNDyne TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy10/14/2025SRPTSarepta TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/10/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform ➝ Market Perform$13.0010/10/2025DYNDyne TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$13.0010/8/2025BHCBausch Health CosWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025DYNDyne TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025MLTXMoonLake ImmunotherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025SRPTSarepta TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSector Perform$14.00 ➝ $16.00(Data available from 10/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBHCBausch Health Cos$9.63B0.24$7.65 per share0.81($0.89) per share-6.96DYNDyne TherapeuticsN/AN/AN/AN/A$6.19 per shareN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/A$7.09 per shareN/ASRPTSarepta Therapeutics$2.48B0.89$2.44 per share9.22$15.99 per share1.41Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBHCBausch Health Cos-$46M$0.2623.831.33N/A0.99%-852.36%5.25%10/29/2025 (Estimated)DYNDyne Therapeutics-$317.42M-$3.86N/AN/AN/AN/A-64.12%-56.75%11/11/2025 (Estimated)MLTXMoonLake Immunotherapeutics-$118.94M-$2.78N/AN/AN/AN/A-40.98%-35.81%11/6/2025 (Estimated)SRPTSarepta Therapeutics$235.24M-$0.87N/A2.06N/A-2.34%-1.03%-0.37%11/5/2025 (Estimated)Latest MLTX, DYN, BHC, and SRPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025DYNDyne Therapeutics-$0.81N/AN/AN/AN/AN/A11/6/2025Q3 2025MLTXMoonLake Immunotherapeutics-$0.89N/AN/AN/AN/AN/A11/5/2025Q3 2025SRPTSarepta Therapeutics$0.02N/AN/AN/A$331.51 millionN/A10/29/2025Q3 2025BHCBausch Health Cos$1.12N/AN/AN/A$2.61 billionN/A8/6/2025Q2 2025SRPTSarepta Therapeutics$0.89$2.02+$1.13$1.89$530.66 million$611.09 million8/5/2025Q2 2025MLTXMoonLake Immunotherapeutics-$0.73-$0.87-$0.14-$0.87N/AN/A7/30/2025Q2 2025BHCBausch Health Cos$0.97$0.90-$0.07$0.40$2.47 billion$2.57 billion7/28/2025Q2 2025DYNDyne Therapeutics-$0.99-$0.97+$0.02-$0.97N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBHCBausch Health CosN/AN/AN/AN/AN/ADYNDyne TherapeuticsN/AN/AN/AN/AN/AMLTXMoonLake ImmunotherapeuticsN/AN/AN/AN/AN/ASRPTSarepta TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBHCBausch Health Cos141.901.310.98DYNDyne Therapeutics0.1716.8316.83MLTXMoonLake Immunotherapeutics0.2116.6516.65SRPTSarepta Therapeutics0.842.891.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBHCBausch Health Cos78.65%DYNDyne Therapeutics96.68%MLTXMoonLake Immunotherapeutics93.85%SRPTSarepta Therapeutics86.68%Insider OwnershipCompanyInsider OwnershipBHCBausch Health Cos19.97%DYNDyne Therapeutics14.14%MLTXMoonLake Immunotherapeutics12.02%SRPTSarepta Therapeutics7.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBHCBausch Health Cos20,700370.81 million296.76 millionOptionableDYNDyne Therapeutics100142.26 million122.15 millionOptionableMLTXMoonLake Immunotherapeutics264.23 million56.51 millionOptionableSRPTSarepta Therapeutics1,37297.71 million90.29 millionOptionableMLTX, DYN, BHC, and SRPT HeadlinesRecent News About These CompaniesTradr 2X Long SRPT Daily ETF5 hours ago | money.usnews.comTradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULFOctober 23 at 11:20 PM | msn.comSarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $18.00October 23 at 9:43 AM | marketbeat.comPrivium Fund Management B.V. Makes New $698,000 Investment in Sarepta Therapeutics, Inc. $SRPTOctober 21 at 6:04 AM | marketbeat.comBlair William & Co. IL Sells 16,942 Shares of Sarepta Therapeutics, Inc. $SRPTOctober 18, 2025 | marketbeat.comSarepta Therapeutics, Inc. $SRPT Shares Bought by Janney Montgomery Scott LLCOctober 18, 2025 | marketbeat.comSarepta Therapeutics (NASDAQ:SRPT) Trading Up 7% - Here's What HappenedOctober 17, 2025 | marketbeat.comWeiss Ratings Reiterates "Sell (D-)" Rating for Sarepta Therapeutics (NASDAQ:SRPT)October 16, 2025 | americanbankingnews.comSarepta’s Not Done With Gene Therapy Yet as New LGMD Asset Yields Promising DataOctober 15, 2025 | biospace.comBSarepta Therapeutics (NASDAQ:SRPT) Receives Sell (D-) Rating from Weiss RatingsOctober 14, 2025 | marketbeat.comAberdeen Group plc Boosts Stake in Sarepta Therapeutics, Inc. $SRPTOctober 14, 2025 | marketbeat.comInspire Investing LLC Raises Stake in Sarepta Therapeutics, Inc. $SRPTOctober 13, 2025 | marketbeat.comCautious Hold Rating on Sarepta Therapeutics Amid Promising but Inconclusive Sirolimus FindingsOctober 13, 2025 | tipranks.comSarepta Therapeutics: A Discounted Valuation Meets Breakthrough PipelineOctober 10, 2025 | seekingalpha.comSarepta Therapeutics (SRPT) Receives a Hold from Mizuho SecuritiesOctober 10, 2025 | theglobeandmail.comSarepta Therapeutics (SRPT) Receives a Buy from JefferiesOctober 10, 2025 | theglobeandmail.comWhat's Going On Sarepta Stock On Wednesday?October 8, 2025 | benzinga.comSarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up After Analyst UpgradeOctober 8, 2025 | marketbeat.comRoyal Bank Of Canada Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $16.00October 8, 2025 | marketbeat.comA Look at Sarepta Therapeutics (SRPT) Valuation Following Recent Share Price GainsOctober 6, 2025 | finance.yahoo.com25,360 Shares in Sarepta Therapeutics, Inc. $SRPT Bought by 111 CapitalOctober 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSoundHound Breaks Critical Resistance: How High Can It Get Now?By Thomas Hughes | September 28, 2025October’s Top 5 Stocks Poised for Big BreakoutsBy Thomas Hughes | October 1, 2025Datavault AI: The New AI Contender Backed by Big FundingBy Jeffrey Neal Johnson | October 1, 2025General Dynamics Hits New Highs: Why It Might Keep ClimbingBy Jeffrey Neal Johnson | October 2, 2025Why Teradyne Is a Core Play in the AI Hardware BoomBy Jeffrey Neal Johnson | September 28, 2025MLTX, DYN, BHC, and SRPT Company DescriptionsBausch Health Cos NYSE:BHC$6.18 -0.20 (-3.06%) Closing price 03:59 PM EasternExtended Trading$6.28 +0.10 (+1.54%) As of 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.Dyne Therapeutics NASDAQ:DYN$17.12 +0.63 (+3.82%) Closing price 04:00 PM EasternExtended Trading$16.57 -0.55 (-3.24%) As of 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Dyne Therapeutics, Inc., a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.MoonLake Immunotherapeutics NASDAQ:MLTX$9.52 +0.06 (+0.63%) Closing price 04:00 PM EasternExtended Trading$9.49 -0.03 (-0.32%) As of 05:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.Sarepta Therapeutics NASDAQ:SRPT$22.80 +0.91 (+4.16%) Closing price 04:00 PM EasternExtended Trading$22.76 -0.05 (-0.20%) As of 05:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene. The company is also developing SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Genevant Sciences; University of Florida; Dyno Therapeutics; Hansa Biopharma; Duke University; Genethon; and StrideBio. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Capital One Just Flashed a Buy Signal—New Highs Could Be Next Why Intuitive Surgical Is a No-Brainer for Long-Term Investors Is Oracle’s AI Rally Over? Wall Street Thinks ORCL Could Hit $400 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
